July 2019
Volume 60, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2019
Glaucoma Drainage Device Coated with Mitomycin C Loaded Opal Shale Microparticles to Inhibit Bleb Fibrosis
Author Affiliations & Notes
  • Huiping Yuan
    Department of Ophthalmology, Harbin Medical University, Harbin,Heilongjiang, China
  • Dong Aimeng
    Department of Ophthalmology, Harbin Medical University, Harbin,Heilongjiang, China
  • Han Liang
    Department of Pharmaceutics, College of Pharmaceutical Sciences, Soochow University, China
  • Zhengbo Shao
    Department of Ophthalmology, Harbin Medical University, Harbin,Heilongjiang, China
  • Pan Fan
    Department of Ophthalmology, Harbin Medical University, Harbin,Heilongjiang, China
  • Xinrong Zhou
    Department of Ophthalmology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, China
  • Footnotes
    Commercial Relationships   Huiping Yuan, None; Dong Aimeng, None; Han Liang, None; Zhengbo Shao, None; Pan Fan, None; Xinrong Zhou, None
  • Footnotes
    Support  the National Natural Science Foundation of China (grant no. 81271000)
Investigative Ophthalmology & Visual Science July 2019, Vol.60, 3750. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Huiping Yuan, Dong Aimeng, Han Liang, Zhengbo Shao, Pan Fan, Xinrong Zhou; Glaucoma Drainage Device Coated with Mitomycin C Loaded Opal Shale Microparticles to Inhibit Bleb Fibrosis. Invest. Ophthalmol. Vis. Sci. 2019;60(9):3750.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Excessive fibrosis is the major cause for the failure of surgical glaucoma drainage device (GDD) implantation. Sustained mitomycin C (MMC) released approaches are promising to help reduce the scar formation. Opal shale (OS) with special characteristics has the potential to be a drug delivery carrier. This study tested the hypothesis that an innovative GDD coated with MMC-loaded OS microparticles (MPs) can reduce the excessive postoperative fibrosis.

Methods : Improved GDDs were designed with MMC-loaded OS MPs physically absorbed on the Ahmed glaucoma valve surface. In vitro, the novel GDD was observed by scanning electron microscopy (SEM) to reveal surface morphology. The release kinetics of MMC were explored using ultraviolet spectrophotometer. Primary human tenon’s fibroblasts (HTFs) and rabbit tenon’s fibroblasts (RTFs) were used to test the biocompatibility and inhibitory of the drug-loaded OS MPs. New Zealand rabbits were divided into three equal groups (n=6/group) for in vivo study. GDD with MMC-OS MPs coating, blank OS MPs coating and normal GDD were implanted in rabbit eyes. Intraocular pressure and bleb morphology were assessed for up to 12 weeks. The pathology of the blebs was observed after euthanasia.

Results : Natural OS MPs successfully attached to the entire GDD surface. 5.45 ± 0.08 μg of MMC was loaded and released in vitro over 90 hours. MMC-loaded OS MPs were able to inhibit fibroblasts proliferation with low toxicity in vitro. In vivo study, IOP was significantly lower in MMC-OS MPs group compared with drug-free groups (P<0.05). Bleb wall thickness in the MMC-OS MPs group of 0.46 ± 0.03 mm was less extensive than in the blank OS MPs and normal GDD groups of 0.63 ± 0.007 mm and 0.61 ± 0.03mm (P<0.05). The pathological examination showed the collagen layer of roof and baseline sides were thinner in the MMC-OS MPs group than in the other two groups at 12 weeks postoperation (P<0.05). There were no statistical differences in the degree of histologic inflammation or histologic fibrosis among the two control groups.

Conclusions : We presented an innovative and improved GDD coated with OS MPs, which were loaded with MMC. The results are consistent with our hypothesis that the ameliorated drainage device was well tolerated and effective in reducing the fibrous reaction in vivo.

This abstract was presented at the 2019 ARVO Annual Meeting, held in Vancouver, Canada, April 28 - May 2, 2019.

 

The design of the MMC-loaded AGV.

The design of the MMC-loaded AGV.

 

AS-OCT measurement results after modified AGV implantation.

AS-OCT measurement results after modified AGV implantation.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×